With calls for American-made drugs on the rise, a Michigan CDMO is scaling up to meet demand

URLhttps://www.fiercepharma.com/manufacturing/calls-f
SourceFierce Pharma
Date Published06/30/2020
Author NameKyle Blankenship
Mentions specific company case(s) of reshoring, kept from offshoring, or transplantYes

Additional Reshoring Information:

Company/Division name Grand River Aseptic Manufacturing (GRAM)
Type of work Manufacturing
Reshoring category:Reshoring
Year reshoring announced:2020
Domestically, the work will be done:In-house
Capital investment ($):60
City reshored to:Grand Rapids
State(s) reshored to:MI
If relevant, work nearshored to:-
Industry(ies):Chemicals
Product(s) reshoredinjectables
What non-domestic negative factors made offshoring less attractive?Quality/rework/warranty
What domestic positive factors made reshoring more attractive?Customer responsiveness improvement, Skilled workforce availability/training, covid-19
Find Reshoring Articles